KEYTRUDA

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug KEYTRUDA contains one active pharmaceutical ingredient (API):

1 Pembrolizumab
UNII DPT0O3T46P - PEMBROLIZUMAB

Pembrolizumab is a humanised monoclonal antibody which binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with ligands PD-L1 and PD-L2. The PD-1 receptor is a negative regulator of T-cell activity that has been shown to be involved in the control of T-cell immune responses.

Read about Pembrolizumab

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
KEYTRUDA Powder for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L01FF02 Pembrolizumab L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
Discover more medicines within L01FF02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 10424P, 10436G, 10475H, 10493G, 11330H, 11352L, 11492W, 11494Y, 11632F, 11646Y, 12119W, 12120X, 12121Y, 12122B, 12123C, 12124D, 12125E, 12126F, 12127G, 12128H, 12129J, 12130K
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 525517020019902
Country: CA Health Products and Food Branch Identifier(s): 02456869
Country: EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria Identifier(s): 127-MBE-0618
Country: EE Ravimiamet Identifier(s): 1691423, 1727074, 1849776
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 1151024002, 1151024002IP
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 529787, 585359
Country: FR Base de données publique des médicaments Identifier(s): 62689214
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 343494, 377764
Country: HK Department of Health Drug Office Identifier(s): 64228
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 7918
Country: JP 医薬品医療機器総合機構 Identifier(s): 4291435A2025
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1077587, 1081202
Country: NL Z-Index G-Standaard, PRK Identifier(s): 127116, 136328
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 18202
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100351618, 100386114
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W64588001
Country: SG Health Sciences Authority Identifier(s): 14881P
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8699636080160
Country: US FDA, National Drug Code Identifier(s): 0006-3026, 0006-3029
Country: ZA Health Products Regulatory Authority Identifier(s): 50/30.1/0957

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.